Physician profile
Michael Bogdanovich
NPI 1386609048
$13,358.92
in general payments reported to CMS, 2019-2025
65 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,979 · 2020: $1,893 · 2021: $2,312 · 2022: $1,910 · 2023: $2,137 · 2024: $2,261 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,241 · Entertainment: $24.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,241.03 |
| Entertainment | $24.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,182.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,167.66 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $937.30 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $831.57 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $815.42 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Janssen Pharmaceuticals, INC | $572.63 | 2019-2022 | |
| Amarin Pharma, INC. | $540.65 | 2019-2023 | |
| Amgen INC. | $528.26 | 2019-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $526.89 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $476.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $421.74 | 2022-2025 | |
| Bausch Health US, LLC | $314.98 | 2019-2022 | |
| Abbott Laboratories | $306.04 | 2019-2025 | Freestyle Libre 3, Afinion 2, Proclaim |
| Pfizer INC. | $260.61 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $245.59 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bogdanovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.